ArticleFrontiers in oncology2021

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.

Tian Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.